Brewin Dolphin Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$164K	Buy	602 +301	+100%	+$80.6K	0.02%	129
2022 Q1	$79K	Hold	301	–	–	0.01%	170
2021 Q4	$66K	Hold	301	–	–	0.01%	181
2021 Q3	$54.6K	Hold	301	–	–	0.01%	188
2021 Q2	$60.7K	Hold	301	–	–	0.01%	175
2021 Q1	$64.7K	Buy	301 +200	+198%	+$43.9K	0.01%	160
2020 Q4	$23.9K	Buy	101 +66	+189%	+$15.1K	﹤0.01%	215
2020 Q3	$9.52K	Buy	+35	New	+$9.66K	﹤0.01%	235

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brewin Dolphin Wealth Management's VRTX Position: Q2 2022 in Review

Brewin Dolphin Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 100% in Q2 2022, buying an estimated $80.6K and bringing the position to 602 shares worth $164K. The position accounts for 0.02% of the portfolio, ranked #129.

Brewin Dolphin Wealth Management first reported a position in VRTX in Q3 2020 and has held it in 8 quarters since. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Brewin Dolphin Wealth Management held 602 shares of Vertex Pharmaceuticals worth $164K as of Q2 2022.
Brewin Dolphin Wealth Management bought 301 Vertex Pharmaceuticals shares in Q2 2022, an estimated $80.6K.
Vertex Pharmaceuticals made up 0.02% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #129 holding.
Brewin Dolphin Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 8 quarters since.
1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.